Navigation Links
OncoSec Announces Clinical Leadership Appointments
Date:6/14/2011

SAN DIEGO, June 14, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today two appointments to its clinical team who will lead the clinical operations of OncoSec's ElectroOncology therapies.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Punit Dhillon, OncoSec's President and CEO, said, "OncoSec has been preparing for its three ElectroOncology clinical studies, which we will launch in the second half of the year, with our in-house leaders and top-tier clinical advisory panel. These new appointments round out our clinical team with additional strategic experience and resources with full focus on advancing these important skin cancer trials. Dr. Goldfarb is a pre-eminent leader in the field of ElectroChemotherapy and Mr. Kitt is a dynamic leader with numerous successes in effectively and efficiently managing clinical trials to completion. We welcome them to the OncoSec team."

Dr. Paul Goldfarb,M.D., F.A.C.S., Medical Director

Dr. Goldfarb will be advising the Company's clinical and regulatory affairs department on all clinical programs. He is a surgical oncologist who has been in private practice in San Diego for over 27 years and a practicing physician for over 40 years. He trained in general surgery at Albert Einstein College of Medicine and in surgical oncology at the Memorial Hospital for Cancer and Allied Diseases and Sloan Kettering Institute for Cancer in New York City, and focuses his practice on the surgical management of cancer. He is currently Clinical Associate Professor of Surgery at the University of California at San Diego, and Associate Medical Director of Oncology at Scripps Health. He has authored numerous peer-reviewed articles related to the use of electroporation to deliver bleomycin in solid tumors an
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoSec Medical Appoints Punit Dhillon as President and CEO
2. OncoSec Medical Featured in Medical Device Daily
3. OncoSec Announces Leadership Team Appointments
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/18/2014)... Sterne, Kessler, Goldstein & Fox P.L.L.C. , an intellectual ... , announced today that it has filed eleven petitions ... U.S. Patent and Trademark Office (USPTO) on behalf of ... BRLI).  These IPR petitions aim to nullify eleven patents ... patents have been asserted against GeneDx in patent infringement ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company ... to regress atherosclerotic plaque, announced the recent presentation ... Division of Cardiology at the David Geffen School ... Heart Association (AHA) Scientific Sessions in Orlando, Florida.  ...
... 2011  If algae is to be the solution for America,s ... make that a reality. Applications are now available for continuing ... retrain workers as general science technicians in the rapidly expanding ... Approximately 55 students will begin classes in ...
... 22, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... announced the Company,s participation at the 23rd Annual Piper Jaffray ... November 29-30, 2011. Ronald M. Lindsay, Ph.D., ... Maier, CFO, will present on Tuesday, November 29, 2011 beginning ...
Cached Biology Technology:AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2
(Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
(Date:8/19/2014)... The University of Texas Health Science Center at San ... (UTSA) today announced the awarding of more than $750,000 ... (SALSI) Innovation Challenge. , Launched in 2003, SALSI is ... and an academic health science center join forces for ... funds collaborative studies, with a focus on public health ...
(Date:8/19/2014)... has been awarded a nearly $40,000 grant from the ... office of the National Park Service (NPS) and U.S. ... one-year study of the energy efficiency and cost effectiveness ... humid climates. , Radiant barriers are reflective thermal insulations ... back, thereby reducing the amount of heat emitted in ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... vegetative cover, strong winds, dry, non-cohesive sandy soils, ... resources of Abu Dhabi Emirate in the United ... stresses, including wind erosion, salinization, waterlogging, landfilling, and ... Dhabi Emirate, land degradation is a matter of ...
... have found a way to save time, money and ... shed light on the biological processes associated with all ... genetics, and postdoctoral associate Matthew C. Hale have provided ... necessary with recent advances in DNA sequencing technology. Instead, ...
... Pfizer Inc., a major biopharmaceutical company, and the Wisconsin ... licensing organization for the University of Wisconsin-Madison, announced May ... embryonic stem (hES) cell patents for the development of ... the rights to work with hES cells for drug ...
Cached Biology News:Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2Random picks better than complicated process in gene identification 2WARF signs license agreement with Pfizer for human embryonic stem cells 2
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
...
Biology Products: